Syngene International Limited has informed the Exchange regarding a press release dated April 29, 2026, titled "Full-year revenue from operations up 3% to Rs. 3,739 Cr; Fourth quarter revenue from operations up 2% year-on-year to Rs. 1,037 Cr.".
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.9 pts more than Nifty Smallcap 250 and 8.9 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene reported muted full-year revenue growth of 3% to Rs. 3,739 Cr for FY26, driven by ongoing impact from a single large-molecule biologics client. Q4 revenue grew 2% YoY to Rs. 1,037 Cr. Operating EBITDA margin compressed significantly from 29% to 25% for the full year, and from 34% to 29% in Q4, reflecting the client impact and costs from ramping up the new biologics manufacturing facility. PAT before exceptional items fell 20% to Rs. 380 Cr for FY26, while Q4 PAT before exceptional items dropped 16% to Rs. 153 Cr. Exceptional items totaling Rs. 462 Mn (net of tax) included gratuity adjustments from new labour codes and employee termination benefits. The company generated Rs. 521 Cr in cash during the year, strengthening its balance sheet. Leadership changes include Kiran Mazumdar-Shaw becoming Executive Chairperson and Siddharth Mittal appointed as next CEO from July 2026.
The stock may face pressure due to significant PAT decline of 20% and EBITDA margin compression of 400 basis points, though the 3% revenue growth and strong cash generation of Rs. 521 Cr provide some support. The company's guidance revision and margin compression signal near-term headwinds from the biologics client.